AIM The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial
Fibrillation” provides recommendations to guide clinicians in the treatment of patients with …

Patients with cirrhosis frequently acquire complex changes in their haemostatic system
including a decreased platelet count and decreased levels of various haemostatic proteins …

The consensus of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in
atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for …

Background: Advanced liver disease is known to increase the risk for bleeding and affects
the hepatic clearance and metabolism of drugs. Subjects with active liver disease were …

Background Whether four direct oral anticoagulants (DOACs) are superior to warfarin in
Asian patients with nonvalvular atrial fibrillation (NVAF) remains unclear. Methods This …

Background: The benefit-risk profile of direct oral anticoagulants (DOACs) compared with
warfarin, and between DOACs in patients with atrial fibrillation (AF) and chronic liver disease …

Atrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent and relevant
healthcare issues. Direct oral anticoagulants (DOACs) are now the first-choice for …

Background Sodium glucose cotransporter 2 inhibitor (SGLT2i) reduces the risk of hard
cardiovascular endpoints in type 2 diabetes mellitus (T2DM) patients with/without …

Background & Aims Studies of the effects of direct oral anticoagulants (DOACs) in patients
with cirrhosis have been limited by their small sample size, inclusion of patients with well …

Context Whether sodium-glucose cotransporter 2 inhibitors (SGLT2is) are associated with
lower risk of new-onset atrial fibrillation (AF) compared with glucagon-like peptide-1 receptor …